{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:19:13Z","timestamp":1788898753064,"version":"build-2803163510"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T00:00:00Z","timestamp":1757808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Johnson & Johnson Innovative Medicine funded this study"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate guselkumab efficacy on dactylitis resolution (DR) and enthesitis resolution (ER), and their impact on subsequent disease control, in patients with active psoriatic arthritis (PsA) and prior inadequate response to tumour necrosis factor inhibitors (TNFi-IR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the Phase IIIb COSMOS trial, 285 adults with TNFi-IR PsA were randomized (2:1) to receive guselkumab 100\u2009mg or placebo at Week (W)0, W4, then every 8\u2009weeks until W44. The Dactylitis Severity Score (DSS) and Leeds Enthesitis Index (LEI) assessed dactylitis and enthesitis, respectively. This post hoc analysis evaluated associations between W24 DR or ER and W48 achievement of stringent disease control measures using logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, 103\/285 (36.1%) patients had dactylitis (DSS\u2009\u2265\u20091) and 190\/285 (66.7%) had enthesitis (LEI\u2009\u2265\u20091). Patients with dactylitis were more likely to have enthesitis, more joint (SJC\/DAPSA) and skin involvement, higher PGA score and lower BMI vs those without dactylitis. Patients with enthesitis were more likely to be female, and have dactylitis, more joints affected (SJC\/TJC\/DAPSA) and worse physical functioning (HAQ-DI\/SF-36 PCS) vs those without enthesitis. Greater proportions of guselkumab- vs placebo-treated patients achieved DR\/ER (W24: 44.8%\/39.7% vs 25.0%\/18.8%); rates increased through W48 among guselkumab-randomized patients (67.2%\/55.6%). W24 resolution was associated with W48 achievement of stringent measures, including ACR50\/70, DAPSA LDA\/remission, PASI100, PASDAS LDA\/VLDA and MDA\/VLDA (odds ratios: DR, 3.28\u201313.38; ER, 2.88\u20136.09).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Guselkumab treatment resulted in high DR\/ER rates through W48 in TNFi-IR PsA patients. W24 DR\/ER was associated with W48 disease control, providing valuable insights for clinical decision-making based on W24 treatment responses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf490","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:53:55Z","timestamp":1757591635000},"source":"Crossref","is-referenced-by-count":2,"title":["Impact of dactylitis and enthesitis resolution on disease control in guselkumab-treated psoriatic arthritis patients with TNFi-IR: COSMOS\n                    <i>post hoc<\/i>\n                    analysis"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-3407","authenticated-orcid":false,"given":"Helena","family":"Marzo-Ortega","sequence":"first","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-4280","authenticated-orcid":false,"given":"Iain B","family":"McInnes","sequence":"additional","affiliation":[{"name":"MVLS College Office, University of Glasgow , Glasgow,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9847-2996","authenticated-orcid":false,"given":"Mohamed","family":"Sharaf","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Middle East TZ LLC , Dubai, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0573-464X","authenticated-orcid":false,"given":"Alen","family":"Zabotti","sequence":"additional","affiliation":[{"name":"Rheumatology Institute, Azienda Sanitaria Universitaria del Friuli Centrale , Udine,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7427-8246","authenticated-orcid":false,"given":"Emmanouil","family":"Rampakakis","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, McGill University , Montreal, QC,","place":["Canada"]},{"name":"JSS Medical Research Inc., Scientific Affairs , Montreal, QC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7715-8226","authenticated-orcid":false,"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5236-424X","authenticated-orcid":false,"given":"Ahmed","family":"Abogamal","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Al Zahra Hospital , Dubai, UAE"},{"name":"Al-Azhar Faculty of Medicine, Al-Azhar University , Cairo,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2132-4074","authenticated-orcid":false,"given":"Pascal","family":"Richette","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Lariboisi\u00e8re Hospital, Paris Cit\u00e9 University, AP-HP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8740-9615","authenticated-orcid":false,"given":"Georg","family":"Schett","sequence":"additional","affiliation":[{"name":"Department of Medicine 3\u2014Rheumatology and Immunology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen , Erlangen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,14]]},"reference":[{"key":"2026020205391673900_keaf490-B1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2026020205391673900_keaf490-B2","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"2026020205391673900_keaf490-B3","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2026020205391673900_keaf490-B4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/acr2.11537","article-title":"Guselkumab, a selective interleukin-23 p19 subunit inhibitor, resolves dactylitis in patients with active psoriatic arthritis: pooled results through Week 52 from two Phase 3 studies","volume":"5","author":"McGonagle","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"2026020205391673900_keaf490-B5","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s10067-024-06921-8","article-title":"Association between enthesitis\/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis","volume":"43","author":"Rahman","year":"2024","journal-title":"Clin Rheumatol"},{"key":"2026020205391673900_keaf490-B6","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2021-220964","article-title":"Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis","volume":"81","author":"Dubash","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026020205391673900_keaf490-B7","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3899\/jrheum.130163","article-title":"Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era","volume":"40","author":"Gladman","year":"2013","journal-title":"J Rheumatol"},{"key":"2026020205391673900_keaf490-B8","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/acr.23249","article-title":"Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"69","author":"Mease","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026020205391673900_keaf490-B9","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/annrheumdis-2017-212681","article-title":"'Deep Koebner\u2019 phenomenon of the flexor tendon-associated accessory pulleys as a novel factor in tenosynovitis and dactylitis in psoriatic arthritis","volume":"77","author":"Tinazzi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026020205391673900_keaf490-B10","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1093\/rheumatology\/keab285","article-title":"Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies","volume":"60","author":"McGonagle","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205391673900_keaf490-B11","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/acr.23174","article-title":"Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: incidence, prevalence, characteristics, and outcome","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026020205391673900_keaf490-B12","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/annrheumdis-2018-214944","article-title":"Identification of myeloid cells in the human enthesis as the main source of local IL-23 production","volume":"78","author":"Bridgewood","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026020205391673900_keaf490-B13","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.micinf.2019.06.009","article-title":"The IL-23\/IL-17 pathway in human chronic inflammatory diseases\u2014new insight from genetics and targeted therapies","volume":"21","author":"Bianchi","year":"2019","journal-title":"Microbes Infect"},{"key":"2026020205391673900_keaf490-B14","doi-asserted-by":"crossref","first-page":"596086","DOI":"10.3389\/fimmu.2020.596086","article-title":"The IL-17\/IL-23 axis and its genetic contribution to psoriatic arthritis","volume":"11","author":"Vecellio","year":"2020","journal-title":"Front Immunol"},{"key":"2026020205391673900_keaf490-B15","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nri3269","article-title":"Inflammation: IL-23 tees off enthesitis","volume":"12","author":"Ray","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"2026020205391673900_keaf490-B16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/1744666X.2020.1857733","article-title":"Guselkumab: the first selective IL-23 inhibitor for active psoriatic arthritis in adults","volume":"17","author":"Boehncke","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"2026020205391673900_keaf490-B17","author":"Johnson & Johnson","year":"2020"},{"key":"2026020205391673900_keaf490-B18","author":"Johnson & Johnson","year":"2024"},{"key":"2026020205391673900_keaf490-B19","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"2026020205391673900_keaf490-B20","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"2026020205391673900_keaf490-B21","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/art.37876","article-title":"Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide DANBIO Registry","volume":"65","author":"Glintborg","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2026020205391673900_keaf490-B22","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s10067-017-3593-x","article-title":"Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry","volume":"36","author":"Harrold","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2026020205391673900_keaf490-B23","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)","volume":"81","author":"Coates","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026020205391673900_keaf490-B24","first-page":"1745","article-title":"Development of an assessment tool for dactylitis in patients with psoriatic arthritis","volume":"32","author":"Helliwell","year":"2005","journal-title":"J Rheumatol"},{"key":"2026020205391673900_keaf490-B25","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.23568","article-title":"Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis","volume":"59","author":"Healy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2026020205391673900_keaf490-B26","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"key":"2026020205391673900_keaf490-B27","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/acr.24046","article-title":"Composite measures of disease activity in psoriatic arthritis: comparative instrument performance based on the efficacy of guselkumab in an interventional Phase II trial","volume":"72","author":"Helliwell","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026020205391673900_keaf490-B28","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2014oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"2026020205391673900_keaf490-B29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026020205391673900_keaf490-B30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2026020205391673900_keaf490-B31","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026020205391673900_keaf490-B32","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s13555-024-01174-4","article-title":"Enthesitis and dactylitis resolution with risankizumab for active psoriatic arthritis: integrated analysis of the randomized KEEPsAKE 1 and 2 trials","volume":"14","author":"Kwatra","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026020205391673900_keaf490-B33","doi-asserted-by":"crossref","first-page":"e001486","DOI":"10.1136\/rmdopen-2020-001486","article-title":"Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis","volume":"7","author":"Giles","year":"2021","journal-title":"RMD Open"},{"key":"2026020205391673900_keaf490-B34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3899\/jrheum.180797","article-title":"Treatment of dactylitis and enthesitis in psoriatic arthritis with biologic agents: a systematic review and metaanalysis","volume":"47","author":"Mourad","year":"2020","journal-title":"J Rheumatol"},{"key":"2026020205391673900_keaf490-B35","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3899\/jrheum.190507","article-title":"Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients","volume":"47","author":"Orbai","year":"2020","journal-title":"J Rheumatol"},{"key":"2026020205391673900_keaf490-B36","first-page":"508","article-title":"Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes","volume":"38","author":"Simons","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2026020205391673900_keaf490-B37","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/annrheumdis-2020-217372","article-title":"Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug: final results by week 52","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf490\/64263267\/keaf490.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf490\/64263267\/keaf490.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf490\/64263267\/keaf490.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:39:28Z","timestamp":1770028768000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf490\/8253722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,14]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf490","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,9,14]]},"article-number":"keaf490"}}